Dr. Alexander R. Giaquinto retired in 2004 as the Senior Vice President for Global Compliance at Schering-Plough Corp. Dr. Giaquinto held a number of positions during his career at Schering-Plough including Associate Director of Pharmaceutical Research and Development, Clinical Manufacturing, Package Development and Aerosol Process Development and Director, Regulatory Affairs. Dr. Giaquinto also held positions at the Schering-Plough Research Institute including Senior Director, Vice President and Senior Vice President of Worldwide Regulatory Affairs.

During his tenure with Schering-Plough, Dr. Giaquinto was instrumental in establishing the Development and Regulatory strategies for the approvals of 74 New Drug Applications (NDA) including Proventil, Vanceril/Vancenase, Rebetrol, Claritin/Claritin-D, Clarinex, Elocon, Integrilin, Temodar, Asmanex and Zetia; nine Biologic License Applications (BLA) including Intron, Peg-Intron and Rebetron; and 28 Abbreviated NDAs. In addition, he was instrumental in establishing the Rx to OTC strategies for Chlortrimeton, Drixoral, Lotrimin, Gyne-Lotrimin and Claritin.

Dr. Giaquinto has served as a member of a number of industry associations including chairman of the Regulatory Affairs Coordinating Committee of the Pharmaceutical Research and Manufacturers Association, the Steering Committee of the International Conference of Harmonization, the American Pharmaceutical Association, the American Association of Pharmaceutical Sciences, the American Society of Clinical Pharmacology and Therapeutics, the New York Academy of Sciences and the Drug Information Association.